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Background. The aim of this study was to evaluate hepatitis E virus (HEV) specific cellular immune responses to truncated ORF2
protein in Iranian patients recovered from HEV infection. Information about HEV-specific immune responses could be useful in
finding an effective way for development of HEV vaccine.Methods.A truncated form ofHEVORF2 protein containing amino acids
112-608 was used to stimulate peripheral blood mononuclear cells (PBMCs) separated from HEV-recovered and control groups.
Finally, the levels of four cytokines, IFN-𝛾 ELISPOT, and cell proliferative responses following stimulation with the truncated
ORF2 protein were assessed in the both groups. Results. The truncated ORF2 protein was able to induce IFN-𝛾 ELISPOT and
cell proliferation responses and to produce significant amounts of IFN-𝛾 and IL-12 cytokines, but low amounts of IL-10 and IL-4
cytokines in vitro. These responses were significantly higher in the recovered group compared to the control group. These results
indicate the antigenic nature of the truncated ORF2 protein and production of T helper type 1 cytokines. Conclusion.The truncated
ORF2 protein can effectively induce significant cellular immune responsesand can be introduced as a potential vaccine candidate.
However, further studies are required to evaluate this protein in vivo.
1. Introduction
Hepatitis E virus (HEV) is a nonenveloped virus with a
nonsegmented positive-sense RNA genome containing three
open reading frames (ORFs) [1, 2]. HEV belongs to the
family Hepeviridae and the genus Hepevirus [3]. The genus
Hepevirus has two species including mammalian HEV and
avian HEV.Themammalian HEV, which infects humans and
several mammalians, is classified into four major genotypes,
namely, genotypes 1, 2, 3, and 4 [4]. The HEV genotypes
share highly conserved immunodominant domains that are
serologically cross-reactive [5].
HEV causes large outbreaks of acute hepatitis in develop-
ing countries where sanitary conditions are inadequate and
the infection is enterically transmitted by the fecal-oral route
especially contaminated water [6, 7]. The zoonotic spread of
the disease is also possible especially in developed countries
where the sporadic cases of the infection have been reported
[2, 4]. Although the infection is usually asymptomatic or
acute self-limiting in general population, but it can progress
to lethal fulminant hepatitis in pregnant women and chronic
hepatitis in immunosuppressed and organ transplant patients
[5, 8].The general mortality rate of HEV infection is between
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1% and 15%, and this level may reach up to 30% due to
fulminate hepatic failure during pregnancy, which may lead
to high rate of spontaneous abortion and premature birth
[5, 9]. Consequently, HEV has become a serious public-
health concern especially in endemic areas, and control and
prevention of this infection are necessary [2]. So far, no
effective treatment or commercial vaccines forHEV infection
are available, and the only way to reduce incidence of the
infection is prevention [2, 10].
Currently, the focus for development of HEV vaccine
is on ORF2 protein. ORF2 encodes capsid protein that
comprises 660 amino acids. HEV capsid protein has several
immune-dominant conserved epitopes that can induce long-
lived immunity; therefore, it has been studied for vaccine
development [11]. However, the full-length capsid protein is
not suitable for vaccine production. Since it is hydrophobic
and insoluble and its immunoreactive epitopes are masked,
much attention has been drawn to the truncated or short
forms of ORF2 protein as protective vaccines [12, 13].
The truncated ORF2 protein, containing amino acids 112
to 660 of the ORF2 protein, self assembles into virus-like
particles and can induce strong immunity [14]. Moreover, 52
amino acids from the C terminus and 111 amino acids from
theN terminus of theORF2 protein do not have any antigenic
domain, andmost antigenic domains have located within 268
amino acids of C terminal of the ORF2 protein [5]. Also,
the truncated ORF2 protein containing amino acids 459 to
607 is needed to produce anti-HEV antibodies; therefore, it
seems that antigenic epitopes are conformational [5]. Anti-
HEVantibodies fromall genotypes cross-reactwith theORF2
protein of genotype 1 [5]; therefore, production of a broadly
protective vaccine seems to be possible by expression the
truncated ORF2 protein of genotype 1 [13].
In the present study, the cellular immune responses to
the truncated ORF2 protein were evaluated in the peripheral
blood mononuclear cells (PBMCs) of individuals recovered
from hepatitis E infection.
2. Materials and Methods
2.1. Ethics Statement. This study (with research project num-
ber D/574) was approved by the Jundishapur University
Ethical Committee, and informed consent was taken from all
the participants.
2.2. Study Group. Forty anti-HEV IgG positive subjects (24,
60% males and 16, 40% females; mean age ± SD, 35.12 ± 9.66
years) and forty-eight anti-HEV IgG negative subjects (28,
58.3% males and 20, 41.7% females; mean age ± SD, 33.06 ±
10.70 years) were randomly selected as HEV-recovered and
control groups to study the immunogenicity of the truncated
ORF2 protein. The presence of anti-HEV IgG antibody was
detected by the commercial ELISA kit (HEV IgG ELISA kit,
DIA.PRO,Milan, Italy). All the participants were negative for
anti-HEV IgM antibody, anti-HAV IgM antibody, anti-HCV
antibodies, and hepatitis B surface antigen (HEV IgM ELISA
kit, HAV IgM ELISA kit, HCV Ab ELISA kit, HBs Ag ELISA
kit, DIA.PRO, Milan, Italy) and had normal ALT level.
2.3. Preparation of Peripheral Blood Mononuclear Cells.
Ficoll-Hypaque (Lymphoflot, Biotest Diagnostics, Germany)
and density gradient centrifugation method were used to
separate peripheral blood mononuclear cells (PBMCs) from
10mL heparinized venous blood sample of the each individ-
ual. Then the cells were washed twice by RPMI 1640 medium
and resuspended in RPMI 1640 plus 10% FCS (Invitrogen,
Carlsbad, CA, USA). Trypan blue staining was used to
evaluate the cells viability.
2.4. Preparation of Truncated ORF2 Protein. A truncated
form of HEV ORF2 protein containing amino acids 112–
608 was produced as described previously [15]. Briefly, a
truncated ORF2 gene encoding amino acids 112–660 of Sar-
55 strain from HEV genotype 1 was optimized for expression
in E. coli and synthesized and cloned into pBluescript II
SK(+) vector by Biomatik Company (Biomatik Corporation,
Cambridge, Canada). The truncated gene was subcloned
into expression vector pET-30a(+) and the recombinant
plasmid pET30a-ORF2(aa 112–660) was constructed. Then, a
193-nucleotide fragment was removed from the nucleotide
sequence of the truncated ORF2 gene by digestion with NheI
restriction enzyme and another truncated form ofORF2 gene
encoding amino acids 112–608 was constructed. The recom-
binant plasmid pET-30a-ORF2(aa 112–608) was transformed
into E. coli BL21 (DE3) using electroporation. Expression
of the truncated ORF2 protein containing amino acids 112–
608 was induced by adding 1mM IPTG to the bacterial
culture followed by 4 hr incubation at 37∘C. The expressed
truncatedORF2 protein was purified byNi2+-chelate-affinity
chromatography (Qiagen, Hilden, Germany). Refolding of
the purified protein was done by dialysis in PBS + 10%
glycerol at 4∘C for 4 hr. Amicon Ultra-4 Centrifugal Filter
Unit (EMD Millipore, Billerica, MA, USA) was used to
improve the concentration and purity of the target protein. To
remove endotoxin contamination that may be obtained dur-
ing protein purification, endotoxin was extracted from the
protein by Toxin Eraser Endotoxin Removal kit (GenScript,
Piscataway, NJ, USA).
2.5. Cell Proliferation Assay. The cell proliferation was car-
ried out by the colorimetric assay using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) as
described previously [16]. For each sample, approximately 1×
10
5 PBMCs/well in RPMI 1640 plus 10% FCS were added to 3
wells of 96-well plates in final volume of 180 𝜇L/well.The first
well was stimulatedwith 10 𝜇g/mL of truncatedORF2 protein
in final volume 20 𝜇L. 20𝜇L/well of phytohemagglutinin
(PHA) (5 𝜇g/mL) (Sigma–Aldrich, St. Louis, MO, USA) was
used as positive control in the second well and the third
well remained unstimulated as negative control. Blankingwas
done by putting RPMI 1640 (20 𝜇L) alone in the well. The
optimal concentrations of truncated ORF2 protein and PHA
and the optimum stimulation duration were determined
based on preliminary experiments. The plate was incubated
in the presence of 5% CO2 at 37
∘C for 4 days, and then 10 𝜇L
of MTT solution (5mg/mL) was added to each well. After
incubation at 37∘C for 4 hr and centrifugation in 1000×g
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Table 1: Results of cytokine, lymphocyte proliferation, and ELISPOT assays in response to truncated ORF2 protein in HEV recovered
individuals and control group.
Parameter Control group (𝑛 = 48) Recovered group (𝑛 = 40) 𝑝 value
IFN-𝛾 17.12 ± 6.93 143.40 ± 52.33 <0.001
IL-12 18.33 ± 9.04 112.75 ± 43.26 <0.001
IL-10 18.72 ± 8.55 27.80 ± 19.55 0.100 (NS)
IL-4 4.30 ± 1.53 4.90 ± 1.49 0.067 (NS)
ELISPOT 4.39 ± 5.51 65.92 ± 58.99 <0.001
Cell proliferation 1.50 ± 0.17 2.01 ± 0.28 <0.001
Cytokine values are represented as picograms per milliliter (pg/mL), the results of ELISPOT assay are expressed as spot forming cells per 105 cells (SFC/105
cells), and the results of cell proliferation assay are shown as proliferation index (PI).
All data are shown as mean ± SD.
NS = nonsignificant.
for 10min, the supernatant was discarded and 100𝜇L of
DMSO was added to each well and mixed by pipetting. The
absorbance of the wells was measured using an ELISA reader
at 570 nm within an hour. The results were expressed as
proliferation index (PI). PI was defined as OD570 stimulated
sample/OD570 unstimulated sample.
2.6. IFN𝛾 ELISPOT Assay. The IFN𝛾 ELISpot assay was
performed by Human IFN-𝛾 ELISPOT Ready-SET-Go kit
(eBioscience, San Diego, CA, USA) to determine HEV-
specific IFN-𝛾-producing cells. According to manufacturer’s
structure, a PVDF bottomed ELISPOT plate (Millipore,
Bedford, MA, USA) was coated with Capture Antibody
solution (100 𝜇L/well) overnight at 4∘C. For each sample,
approximately 1 × 105 PBMCs/well in RPMI 1640 plus 10%
FCS were added to 3 wells of the 96-well ELISPOT plate
in final volume of 150𝜇L/well. The first well was stimulated
with 10 𝜇g/mL truncated ORF2 protein. Five 𝜇g/mL of PHA
was used as positive control in the second well, and the
third well remained unstimulated as negative control. The
optimal count of PBMC in each well, the optimal con-
centrations of truncated ORF2 protein and PHA, and the
optimum duration of stimulation were determined based
on preliminary experiments. The plate was incubated at
37∘C for 24 hr. Then, the cells and medium were removed
and the wells were washed 3 times with ELISPOT Wash
Buffer. The plate was incubated with Biotinylated Detection
Antibody (100 𝜇L/each well) at 4∘C overnight and washed
4 times with ELISPOT Wash Buffer. In the next step, the
plate was incubated with 100 𝜇L/well of Avidin-Horseradish
Peroxidase reagent at room temperature for 45min and
washed with ELISPOT Wash Buffer and 1x PBS. Finally, the
dark purple spots were developed by adding 100 𝜇L/well AEC
(3-amino-9-ethylcarbazole), followed by incubation at room
temperature. The plate was washed 3 times with 200𝜇L/well
distilled water and dried at room temperature, and then a
dissection stereoscopewas used to count the number of spots.
The results were shown as spot forming cells (SFCs) per 105
cells, while each spot was considered as one HEV-specific
IFN-𝛾 secreting cell.
2.7. Cytokine Assay. PBMCs of each sample were stimulated
with the truncated ORF2 protein (10 𝜇g/mL) at 37∘C. In
addition, five 𝜇g/mL PHA was used as positive control. The
optimal concentrations of truncated ORF2 protein and PHA
and the optimum stimulation duration were determined
based on preliminary experiments. Culture supernatants
were harvested after 1-2 days and used tomeasure amounts of
four cytokines (IL-4, IL-12 p70, IFN-𝛾, and IL-10). Cytokine
assay was performed by commercially available ELISA kits
(eBioscience, San Diego, CA, USA) according to the manu-
facturer’s instructions. The results were shown as picograms
per milliliter (pg/mL). The limits of sensitivity of the assays
were 1.3 pg/mL for IL-4, 1.0 pg/mL for IL-10, 2.1 pg/mL for IL-
12 p70, and 0.99 pg/mL for IFN-𝛾.
2.8. Statistical Analysis. SPSS 17 Package program (SPSS Inc.,
Chicago, USA) was used for statistical analysis, and 𝑝 values
below 0.05 indicated statistical significance. The data were
analyzed and compared by the Mann-Whitney 𝑈 test or
independent 𝑡-test. All data were expressed as mean ± SD.
3. Results
3.1. Cell Proliferative Response to Truncated ORF2 Protein.
Proliferation of PBMCs in response to the truncated ORF2
protein was measured in the control and HEV-recovered
groups. The cell proliferative responses to truncated ORF2
protein in the control andHEV-recovered groups were 1.50±
0.17 and 2.01 ± 0.28, respectively. The corresponding figures
following stimulation with PHA were 2.91 ± 0.37 and 2.81 ±
0.33 in the control and recovered groups, respectively (𝑝 =
NS).Overall, the recovered group showed significantly higher
cell proliferation compared to the control group (𝑝 < 0.001)
(Table 1, Figure 1).
3.2. IFN-𝛾 ELISPOT Responses to the Truncated OR2 Protein.
The frequencies of IFN-𝛾-secreting cells in PBMCs of HEV-
recovered and control groups were assessed in response to
truncated ORF2 protein by ELISPOT assay. IFN-𝛾 ELISPOT
responses following stimulation with the truncated ORF2
protein in the control andHEV-recovered groups were 4.39±
5.51 and 65.92 ± 58.99, respectively. ELISPOT responses to
PHA in the control and recovered groups were 223.41±94.58
and 228.25 ± 123.41, respectively (𝑝 = NS). Overall, IFN-𝛾
ELISPOT responseswere significantly higher in the recovered
























Figure 1: Cell proliferative responses in HEV-recovered individuals
and control group. Proliferative responses to the truncated ORF2
protein are significantly higher in HEV-recovered group compared
to the control group, while both groups showed good nonspecific
stimulation with PHA. The results are shown as proliferation index
(mean ± SD PI).
group compared to the control group (𝑝 < 0.001) (Table 1,
Figure 2).
3.3. Cytokine Production in Responses to Truncated ORF2
Protein. Significant amounts of IFN-𝛾 and IL-12 cytokines
but low amounts of IL-10 and IL-4 cytokines were produced
following stimulation with the truncated ORF2 protein.
Comparison between the two groups revealed no significant
differences in the levels of IL-10 (𝑝 = 0.100) and IL-4
(𝑝 = 0.067), while IFN-𝛾 and IL-12 p70 were significantly
higher in the recovered group compared to the control group
(𝑝 < 0.001). Stimulation with PHA resulted in almost similar
expression of all cytokines in the control and recovered
groups, including 11.96 ± 4.55 and 11.29 ± 3.9 for IL-4 (𝑝 =
NS), 199.45 ± 108.43 and 204.97 ± 103.61 for IL-10 (𝑝 = NS),
109.91 ± 32.86 and 103.22 ± 25.9 for IL-12 (𝑝 = NS), and
410.37 ± 46.96 and 418.37 ± 75.65 for IFN-𝛾 (𝑝 = NS),
respectively (Table 1, Figure 3).
4. Discussion
HEV causes self-limited acute hepatic infection worldwide
and especially in developing countries where the disease is
endemic and 30% to 80% of the adult population has anti-
HEV antibody [17]. The infection is more severe in pregnant
women and patients with underlying liver problems and
may progress to lethal fulminant hepatitis [5, 8]. Information
about HEV specific cellular immune responses could be




























Figure 2: IFN-𝛾 ELISPOT responses in HEV-recovered and control
groups. IFN-𝛾 ELISPOT responses to the truncated ORF2 protein
are significantly higher in the recovered group compared to the
controls, while both groups showed good nonspecific stimulation
with PHA. The results are shown as spot forming cells per 105 cells
(SFC/105 cells).
vaccine, in particular as any protective vaccine for HEV
infection is not still licensed [2, 9]. However, some stud-
ies have evaluated HEV-specific cellular immune responses
among different groups [6, 18–20], but current information
on cellular immune responses against HEV is not sufficient
to prevent HEV infection. Therefore, this study aimed to
evaluate HEV-specific cellular immune responses to the
truncated ORF2 protein in the recovered individuals from
HEV infection.
In the present study, a significant increase in the cell
proliferation and IFN-𝛾 ELISPOT responses following
stimulation with the truncated ORF2 protein were found
in the HEV-recovered subjects, while both groups showed
good nonspecific stimulation with PHA. Therefore, the
increase in responses induced by truncated ORF2 protein
was specific in the recovered group.These results indicate the
antigenic nature of the truncated ORF2 protein. Suneetha
et al. reported a similar increase in the HEV-specific T-cell
responses by PBMCs obtained from recovered individuals
from HEV infection. The stimulating antigen in their study
was overlapping peptide pools and not the whole HEVORF2
protein [20]. Regarding the full length ORF2 protein, Husain
et al. presented similar results in acute hepatitis E patients
compared to the controls [21]. It has been shown that ORF2
protein has several HTL (helper T-lymphocyte) dominant
immunogenic regions and therefore it is a good antigen
to elicit high and long-lasting specific anti-HEV immune
responses [22]. The HEV-specific T-helper cell responses,
especially against capsid protein, play a critical role in
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Figure 3: The levels of IL-4, IL-10, IL-12 p70, and IFN-𝛾 cytokines
in HEV-recovered and control groups following stimulation with
the truncated ORF2 protein. Significant amounts of IFN-𝛾 and IL-
12 cytokines but low amounts of IL-10 and IL-4 cytokines were
produced. IL-12 p70 and IFN-𝛾 cytokines production following
stimulation with the truncated ORF2 protein was significantly
higher in the recovered group compared to the control group, while
there were no significant differences in the levels of IL-10 and IL-
4 between the two groups. Both groups showed almost similar
expression of all cytokines following stimulation with PHA. Results
are shown as mean ± SD pg/mL.
clearing and controlling viral infections, either directly
through cytokines production or indirectly by activating
cytotoxic T cells [1].
Production of T-helper type 1 (Th1) cytokines such as
IFN-𝛾, TNF-𝛼/𝛽, IL-2, IL-3, and IL-12 have been implicated
in viral clearance or resistance to infection, while production
of Th2 cytokines such as IL-4, IL-5, IL-13, IL-6, and IL-10
cytokines is associated with progression of the infection or
viral persistence [23–28]. In the present study, the truncated
ORF2 protein could significantly stimulate PBMCs to pro-
duce IFN-𝛾 and IL-12 but little or no IL-4. These results
demonstrate that the Th1 responses are induced against the
truncated ORF2 protein. The results of this study being
consistent with those of others suggest that viral proteins
that can shift immune responses to Th1, rather than Th2,
may have a better chance of success as a vaccine candidate
against HEV infection [29]. All participants in control and
recovered groups showed almost similar expression of all
cytokines following stimulation with PHA. Therefore, the
increase in production of IFN-𝛾 and IL-12 cytokines follow-
ing stimulation with truncated ORF2 protein was specific in
the recovered group.
The results of the previous studies have shown that the
production of Th1 cytokines such as IL-12 and IFN-𝛾 during
HEV infection results in self-limiting hepatitis E, suggesting
the role of these cytokines in the recovery and clearance
of hepatitis E, while the Th2 cytokines increase in fatal
fulminant hepatitis E, especially during pregnancy [18, 27, 30,
31]. In Saravanabalaji et al. study, levels of IFN-𝛾 and IL-12
cytokines following stimulation of PBMCs by recombinant
ORF2 protein were higher in recovered patients than those
with fatal fulminant hepatitis E, while IL-10 was higher in
fatal patients [30]. In Pal et al. study, high levels of IL-4 and
IL-10 were observed in pregnant women with acute hepatitis
E following stimulation of PBMCs with different peptides of
HEV ORFs, while the level of IFN-𝛾 was low in this group
[27]. In Srivastava et al. study, the IFN-𝛾 production following
stimulation with ORF2 protein was higher in patients with
acute HEV infection compared to control [6].
In this study, antigenic properties of the expressed ORF2
protein in E. coli BL21 cell were evaluated. Among the
various microorganisms and systems available for protein
production,E. coliBL21 containing pET-derived plasmids has
become the most commonly used expression system because
of its high expression capabilities, protein production with
high purity, low cost, simple and fast cultivation, its well-
known genetics, and therefore ease of genetic manipulation
[32]. However, there are a variety of factors that affect
the expression level as well as the solubility and especially
biological function of overexpressed proteins. One of the
ways to improve the expression of foreign protein in E. coli is
codon optimization, which results in selection of host favorite
codons and elimination of high GC contents [33, 34]. By
evaluating the antigenic properties and immunogenicity of
the truncated ORF2 protein, it was indicated that this protein
has biological function and can stimulate specific anti-HEV
immune responses.
In conclusion, the truncated ORF2 protein is able to
induce significant cellular immune responses and production
of Th1 cytokines in vitro and therefore can be introduced as
a potential vaccine candidate for HEV infection. However
further studies are required to evaluate this protein in vivo.
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